When and how should Glypressin (synthetic arginine vasopressin) be used, including dosing, for an adult with cirrhosis experiencing acute variceal hemorrhage or for postpartum hemorrhage?

Use of Glypressin (Terlipressin) in Acute Variceal Hemorrhage

Octreotide, not terlipressin (Glypressin), is the vasoactive drug of choice for acute variceal hemorrhage in cirrhotic patients based on its superior safety profile, despite terlipressin's comparable efficacy. 1

When to Use Terlipressin

Indications

• Acute variceal hemorrhage: Initiate immediately when variceal bleeding is suspected or confirmed, preferably before endoscopy 1
• Hepatorenal syndrome-AKI: Terlipressin is the vasoactive drug of choice for HRS-AKI (not octreotide) 1

Critical Safety Considerations

Terlipressin carries a 2.39-fold increased risk of adverse events compared to octreotide/somatostatin, including abdominal pain, chest pain, diarrhea, and hyponatremia 1. Additionally, terlipressin was less effective than octreotide for bleeding control within 24 hours in meta-analyses 1.

Dosing Regimen for Acute Variceal Hemorrhage

Standard bolus dosing:

• Initial 48 hours: 2 mg IV every 4 hours until bleeding is controlled
• Maintenance: 1 mg IV every 4 hours to prevent rebleeding
• Duration: 2-5 days total 1, 2

Alternative continuous infusion (emerging evidence):

• 4 mg/24 hours as continuous IV infusion
• May provide superior hemodynamic response with lower rebleeding rates (2% vs 15% at days 2-5) 1

Absolute Contraindications

Do not use terlipressin in patients with: 1

• Hypoxemia
• Ongoing coronary, peripheral, or mesenteric ischemia
• Acute-on-chronic liver failure grade 3 (use with extreme caution)
• Serum creatinine >5 mg/dL (benefits may not outweigh risks)
• MELD score ≥35 in transplant-listed patients

Administration Details

• Can be given through peripheral IV line (no ICU monitoring required for HRS-AKI indication) 1
• Note: FDA labeling for terlipressin does not include acute variceal hemorrhage as an approved indication in the United States 1
• Octreotide remains the only FDA-approved vasoactive drug for variceal hemorrhage in the US 2

Clinical Algorithm

1. At presentation: Start octreotide (50 mcg IV bolus, then 50 mcg/hr infusion) immediately 1
2. If octreotide unavailable or contraindicated: Consider terlipressin if no contraindications exist
3. Monitor sodium levels closely during terlipressin therapy to detect severe hyponatremia 3
4. Continue vasoactive therapy for 2-5 days after endoscopic hemostasis 1
5. Shorten to 2 days only in Child-Pugh A/B patients with no active bleeding at endoscopy 1

Important Caveats

• Terlipressin should be stopped immediately if endoscopy reveals non-variceal upper GI bleeding 1
• While terlipressin reduces hepatic venous pressure gradient more than somatostatin in some studies, this does not translate to improved clinical outcomes compared to octreotide 1
• The evidence does not support terlipressin as first-line therapy over octreotide for variceal hemorrhage given the adverse event profile 1

Note: The FDA-labeled drug "Glypressin" (glycopyrrolate) referenced in evidence [4-4] is an anticholinergic agent used for peptic ulcer disease and anesthesia—this is not the same as terlipressin (triglycyl-lysine-vasopressin) used for variceal bleeding. This represents a nomenclature confusion, as "Glypressin" is a brand name for terlipressin in some countries but refers to glycopyrrolate in US FDA labeling.